The Norwegian Prostate Cancer Biomarker Consortium

Who are we?

In 2013,  Dr. Ian Mills and Prof. Kristin Austlid Taskén  gathered 27 PIs from 7 independent institutions across Norway, Sweden and the US to form the Norwegian Prostate Cancer Biomarker Consortium, spanning professions like urologists, oncologists, geneticists, pathologists, molecular biologists, biostatisticians and bioinformaticians. The Consortium received the  Movember Team Award in 2013 for their aim to identify biomarkers for indolent and aggressive prostate cancer.

What are we doing ?

The members of the consortium work in multidisciplinary teams and structure their work through 7 work packages, profiling molecules in tissue, blood and urine  from prostate cancer patients through advanced  technologies. Candidate biomarkers identified are scored and tested for clinical utility and value.

 

The Consortium members gathers each year to share new knowledge on progress made in technologies and discoveries.

Main achievements

  • 120 candidate biomarker identified

  • 27 original articles published

  • 2 Review articles

  • 3 Patents

  • 8 Grants (incl ERC starting grant)

  • 4 industry presentations

  • 13 popular scientific reports